New E. coli testing begins next week

 Resize text         Printer-friendly version of this article Printer-friendly version of this article

USDA will begin testing beef trim for non-O157 strains of E. coli on June 4, according to a notice to be published in the Federal Register. The testing will focus on six Shiga toxin-producing Escherichia coli (STEC), in addition to E. coli O157:H7.

According to the Center for Infectious Disease Research & Policy (CIDRAP), these six STEC strains account for 80 percent of non-O157 E. coli illnesses infections. The Centers for Disease Control and Prevention estimates non-O157 E. coli strains cause 112,000 illnesses annually, with about 36,700 of those attributed to beef.

Initially, USDA’s Food Safety and Inspection Service will target beef trim for testing, but plans to announce the date it intends to implement routine testing for the additional STECs in other products, including ground beef, that currently are tested for E. coli O157:H7.

Industry stakeholders have expressed concerns that USDA lacks data on the actual prevalence of non-O157 STECs on beef carcasses, and that reliable tests for the pathogens are not readily available for commercial use. In its notice, however, FSIS refutes these claims. “FSIS has concluded that a baseline is neither necessary nor warranted before implementation of the FSIS verification sampling and testing program,” the agency writes. “These organisms are present in beef products in the United States.”

FSIS does, however, plan to conduct a carcass baseline survey next year, which will analyze samples from pre-treated carcasses for the presence of the pathogens E. coli O157:H7 and the specified STECs, Salmonella, and indicator bacteria (generic E. coli, coliforms, and Enterobacteriaceae). As it plans the research, FSIS will share the study design with stakeholders.

As for the logistics of testing, FSIS says screening and confirmation methods and materials for non-O157 STEC are available to industry. Some establishments have been testing for non-O157 STECs for a year or more. Also, FSIS has reviewed validation data from test kits from several manufacturers and issued no-objection-letters for their commercial use.

In related news, USDA’s Office of the Inspector General this week released results of an audit of beef plants, outlining the industry’s aggressive efforts to protect the beef supply from E. coli contamination.

"We found that industry was performing thousands of E. coli tests daily generally following the Food Safety and Inspection Service’s recommended procedures.  Overall, industry was taking  appropriate steps to help ensure that U.S. beef is safe from E. coli contamination, recognizing  that regardless of how stringently the industry tests for E. coli, there is always an inherent risk of  its presence in slaughter plants,” the report concludes.

The audit report is available online from USDA.

Read the Federal Register notice regarding STEC testing for beef.



Comments (2) Leave a comment 

Name
e-Mail (required)
Location

Comment:

characters left

Jaime    
USA  |  June, 01, 2012 at 10:52 AM

Is the intent of the regulations to make beef safe to eat without cooking? Or, is the intent to make US beef unaffordable? Or, is the intent to give foreign meat suppliers an advantage over US producers? What would keep the lying Communist Red Chinese or other Communist-inspired country, from repeatedly lying about the results of food safety tests so as to defeat America's ag industry by importing cheaper meat?

Steve Kilmer    
Canada  |  June, 29, 2012 at 03:25 PM

For future reference, a small Montreal-based company, Thallion Pharmaceuticals, has partnered with France's state-owned LFB Biotechnologies to develop the world's first treatment for Shiga toxin-producing E. coli (STEC) infection. Shigamabs uses a proven anti-toxin approach to neutralize the two types of toxins secreted by pathogenic E. coli with the intent of preventing the incidence and/or reducing the severity of a life-threatening kidney disease called hemolytic ureic syndrome (HUS). An additional benefit of this anti-toxin approach is that it is bacterial strain independent. The company announced positive Phase 2 (primarily safety) data a few weeks ago and plans on launching a single Phase 3 trial next year. Anyway, just thought that it would make sense to get Thallion and its Shigamabs drug on your radar.


RTV-X Series Utility Vehicles

Get ready for a whole new RTV experience. Kubota RTVs have been the best-selling diesel utility vehicles in North America since ... Read More

View all Products in this segment

View All Buyers Guides

Feedback Form
Leads to Insight